Global Markets Direct’s, ‘Compugen Ltd. – Product Pipeline Review -2015′, provides an overview of the Compugen Ltd.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Compugen Ltd.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

• The report provides brief overview of Compugen Ltd. including business description, key information and facts, and its locations and subsidiaries
• The report reviews current pipeline of Compugen Ltd.’s human therapeutic division and enlists all their major and minor projects
• The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
• Special feature on out-licensed and partnered product portfolio
• The report summarizes all the dormant and discontinued pipeline projects
• Latest company statement
• Latest news and deals relating to the Compugen Ltd.’s pipeline products

Reasons to buy

• Evaluate Compugen Ltd.’s strategic position with total access to detailed information on its product pipeline
• Assess the growth potential of Compugen Ltd. in its therapy areas of focus
• Identify new drug targets and therapeutic classes in the Compugen Ltd.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
• Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
• Develop strategic initiatives by understanding the focus areas of Compugen Ltd. and exploit collaboration and partnership opportunities
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Plan mergers and acquisitions effectively by identifying the most promising pipeline of Compugen Ltd.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Explore the dormant and discontinued projects of Compugen Ltd. and identify potential opportunities in those areas
• Avoid Intellectual Property Rights related issues

Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Compugen Ltd. Snapshot 6
Compugen Ltd. Overview 6
Key Information 6
Key Facts 6
Compugen Ltd. - Research and Development Overview 7
Key Therapeutic Areas 7
Compugen Ltd. - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Partnered Products 12
Partnered Products/Combination Treatment Modalities 13
Compugen Ltd. - Pipeline Products Glance 14
Compugen Ltd. - Early Stage Pipeline Products 14
Preclinical Products/Combination Treatment Modalities 14
Discovery Products/Combination Treatment Modalities 15
Compugen Ltd. - Drug Profiles 16
CGEN-15001 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
CGEN-15021 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
CGEN-15031 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
CGEN-15051 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
CGEN-15091 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
CGEN-25008 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
CGEN-25009 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
CGEN-25068 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
CGEN-856S 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Monoclonal Antibody to Inhibit CGEN-15022 for Epithelial Cancer 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Monoclonal Antibody to Inhibit CGEN-15049 for Cancer 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Monoclonal Antibody to Target CGEN-15001T for Cancer 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Recombinant Proteins for Autoimmune and Inflammatory Diseases 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
CGEN-15029 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Monoclonal Antibody 2 for Oncology 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Monoclonal Antibody 3 for Oncology 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Monoclonal Antibody 4 or Oncology 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Monoclonal Antibody 5 for Oncology 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Monoclonal Antibody Conjugate 1 for Cancer 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Monoclonal Antibody Conjugate 2 for Cancer 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Monoclonal Antibody for Cancer 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Monoclonal Antibody to Inhibit CGEN-15027 for Cancer 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Monoclonal Antibody to Inhibit CGEN-15052 for Cancer 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Monoclonal Antibody to Inhibit CGEN-15092 for Oncology 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Monoclonal Antibody to Target CGEN-928 for Multiple Myeloma 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Compugen Ltd. - Pipeline Analysis 44
Compugen Ltd. - Pipeline Products by Target 44
Compugen Ltd. - Pipeline Products by Molecule Type 45
Compugen Ltd. - Pipeline Products by Mechanism of Action 46
Compugen Ltd. - Recent Pipeline Updates 47
Compugen Ltd. - Dormant Projects 51
Compugen Ltd. - Locations And Subsidiaries 52
Head Office 52
Other Locations & Subsidiaries 52
Appendix 53
Methodology 53
Coverage 53
Secondary Research 53
Primary Research 53
Expert Panel Validation 53
Contact Us 53
Disclaimer 54

List of Tables

Compugen Ltd., Key Information 6
Compugen Ltd., Key Facts 6
Compugen Ltd. - Pipeline by Indication, 2015 8
Compugen Ltd. - Pipeline by Stage of Development, 2015 10
Compugen Ltd. - Monotherapy Products in Pipeline, 2015 11
Compugen Ltd. - Partnered Products in Pipeline, 2015 12
Compugen Ltd. - Partnered Products/ Combination Treatment Modalities, 2015 13
Compugen Ltd. - Preclinical, 2015 14
Compugen Ltd. - Discovery, 2015 15
Compugen Ltd. - Pipeline by Target, 2015 44
Compugen Ltd. - Pipeline by Molecule Type, 2015 45
Compugen Ltd. - Pipeline Products by Mechanism of Action, 2015 46
Compugen Ltd. - Recent Pipeline Updates, 2015 47
Compugen Ltd. - Dormant Developmental Projects,2015 51
Compugen Ltd., Subsidiaries 52

List of Figures

Compugen Ltd. - Pipeline by Top 10 Indication, 2015 8
Compugen Ltd. - Pipeline by Stage of Development, 2015 10
Compugen Ltd. - Monotherapy Products in Pipeline, 2015 11
Compugen Ltd. - Pipeline by Top 10 Target, 2015 44
Compugen Ltd. - Pipeline by Top 10 Molecule Type, 2015 45
Compugen Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2015 46